Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Royalty Pharma plc

< Previous 1 2 Next >
Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
Royalty Pharma Announces Dividend Increase
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX TEVA
Royalty Pharma Reports Third Quarter 2023 Results
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
Royalty Pharma Declares Fourth Quarter 2023 Dividend
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
Royalty Pharma Appoints Eric Schneider as Chief Technology Officer
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
From Royalty Pharma plc
Via GlobeNewswire
Tickers ASND RPRX
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
Royalty Pharma Reports Second Quarter 2023 Results
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
Royalty Pharma Declares Third Quarter 2023 Dividend
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
Royalty Pharma Reports First Quarter 2023 Results
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
Royalty Pharma To Present At The BofA Securities 2023 Health Care Conference
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
Royalty Pharma Declares Second Quarter 2023 Dividend
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
Royalty Pharma to Announce First Quarter 2023 Financial Results on May 9, 2023
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
Royalty Pharma Announces $1.0 Billion Share Repurchase Program
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million
From Royalty Pharma plc
Via GlobeNewswire
Tickers PRTC RPRX
Royalty Pharma Raises Full Year 2023 Guidance
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
Royalty Pharma Appoints Ashwin Pai as Executive Vice President, Investments
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
Royalty Pharma Reports Q4 and Full Year 2022 Results
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
Tickers RPRX
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
From Royalty Pharma plc
Via GlobeNewswire
Tickers IONS RPRX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback